Enfusion, Inc. [Rocket]

Overview

Enfusion, Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
08/18/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
08/18/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
08/18/2023	4	LEIBOWITZ LAWRENCE E (Director) has filed a Form 4 on Enfusion, Inc.
08/18/2023	8-K	Quarterly results
08/15/2023	4	Bastone Bronwen (Chief People Officer) has filed a Form 4 on Enfusion, Inc.
08/15/2023	4	Groman Dan (Chief Technology Officer) has filed a Form 4 on Enfusion, Inc.
08/15/2023	4	LEIBOWITZ LAWRENCE E (Director) has filed a Form 4 on Enfusion, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19
Revenues	111.7	79.6	59.0
Revenue growth	40.4%	34.8%
Cost of goods sold	31.8	21.4	17.0
Gross profit	79.9	58.2	42.1
Gross margin	71.5%	73.2%	71.3%
Sales and marketing	51.7	9.9	7.4
Research and development	153.4	6.3	4.1
General and administrative	150.6	35.9	16.6
EBIT	-275.9	6.1	13.9
EBIT margin	-247.0%	7.6%	23.5%
Pre-tax income	-281.7	4.5	13.1
Income taxes	0.6	0.4	0.5
Tax rate		9.6%	3.7%
Net income	-158.3	4.1	12.7
Net margin	-141.7%	5.1%	21.4%

Diluted EPS	($1.91)
Shares outstanding (diluted)	83.0

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.